Analysts’ Viewpoint
The global ischemia reperfusion injury therapeutics market is driven by rise in prevalence of cardiovascular diseases, increase in geriatric population, and surge in awareness about ischemia reperfusion injuries among healthcare professionals and patients. Advancements in technology and development of new and effective therapies present significant opportunities for manufacturers in the market. Furthermore, government initiatives and funding for research & development of new therapies support market development.
The COVID-19 pandemic led to a decrease in the number of elective surgeries, leading to a decline in number of cases of ischemia reperfusion injury. Additionally, the pandemic led to a decrease in funding for research & development. However, surge in focus on COVID-19 treatments contributed to new discoveries and advancements that could benefit the treatment of ischemia reperfusion injury in future.
Ischemia-reperfusion injury (IRI) occurs when blood flow to an area of tissue is blocked (ischemia) and subsequently restored (reperfusion). This could happen during situations, such as heart attack, stroke, or surgery, where a blood vessel is temporarily blocked and then reopened. During ischemia, the tissue is deprived of oxygen and nutrients, which could cause damage to cells and tissues. When blood flow is restored (reperfusion), the sudden influx of oxygen can cause a cascade of harmful reactions, including inflammation and the generation of reactive oxygen species (ROS), leading to further damage to the tissue. This injury could lead to functional and structural impairments of the organ, such as myocardial infarction, stroke, and kidney injury.
A rise in a number of patients requiring treatment for IRI due to an increase in the incidence of cardiovascular diseases and organ transplants is driving market expansion. The surge in healthcare expenditure and rise in awareness about IRI and its treatment options are propelling market progress.
Development of new drugs and therapies that can effectively target and treat IRI and expansion of existing treatments into new indications are augmenting the market. Increase in incidence of IRI-related conditions, such as heart attack and stroke, is expected to bolster global ischemia reperfusion injury therapeutics market growth. Development of new diagnostic tools and increase in usage of telemedicine and other digital technologies to improve patient outcomes present significant opportunities for companies in the industry.
Increase in patient population in need of IRI treatment due to rise in prevalence of cardiovascular diseases, such as heart attack and stroke, is driving ischemia-reperfusion injury therapeutics market share. The ischemia-reperfusion injury could occur during certain medical procedures, such as angioplasty, and is a leading cause of tissue damage in patients with cardiovascular disease. Ischemia-reperfusion injury therapeutics market demand is expected to be driven by aging population and increase in risk factors for cardiovascular diseases, such as obesity and diabetes.
Cardiovascular diseases (CVDs) is a leading cause of death across the world. According to the World Health Organization (WHO), CVDs are a major cause of death globally, accounting for 17.9 million deaths per year. Prevalence of CVDs is increasing due to aging population and surge in risk factors such as obesity and diabetes. Additionally, CVDs are more common in low- and middle-income countries, where access to healthcare and preventative measures is limited.
Surge in awareness about IRI among healthcare professionals and patients is driving the demand for effective treatments. Awareness among healthcare professionals about this condition is rising due to education and training. This, in turn, is likely to increase diagnosis and treatment. Patients are more informed about the condition and its potential complications. Surge in awareness about IRI is leading to rise in research & development and introduction of a number of products to treat the condition.
Awareness about IRI is rising due to increase in research and understanding of the mechanisms involved and the potential interventions that could be used to mitigate its effects. Additionally, usage of ischemia reperfusion in various clinical settings, such as organ transplantation and cardiopulmonary bypass surgery, has led to increase in attention and awareness about the condition. Furthermore, growing interest in regenerative medicine has led to increase in focus on the role of ischemia reperfusion in tissue injury and repair. Therefore, rise in awareness among healthcare professionals and patients is projected to drive the demand for ischemia reperfusion injury therapeutics during the forecast period.
Development of new and effective therapies for IRI that are more effective and have fewer side effects than current therapies is expected to bolster ischemia reperfusion injury therapeutics market growth. This is likely to lead to increase in demand for these therapies and rise in revenue of companies. Additionally, ongoing research and development in IRI therapeutics could lead to discovery of new targets and mechanisms for therapy. This, in turn, is projected to accelerate market growth.
Development of new and effective therapies, such as drugs that can target specific pathways or molecules involved in the injury process, in anticipated to propel the industry. For instance, drugs that inhibit inflammation or oxidative stress could help reduce tissue damage caused by IRI.
Usage of regenerative medicine techniques, such as stem cell therapy, to repair or replace damaged cells and tissues could lead to the development of therapies that can help restore function to the affected area and reduce the risk of complications. Additionally, new technologies, such as remote monitoring and telemedicine, are being used to improve the diagnosis and treatment of IRI.
Recent developments in new therapies for IRI include usage of stem cells and exosomes, pharmacological agents such as statins and phosphodiesterase inhibitors, and utilization of remote ischemic preconditioning. Other promising areas of research are usage of hyperbaric oxygen therapy and utilization of extracorporeal devices to remove damaging molecules from the blood.
In terms of treatment, the drug therapy segment dominated the global ischemia reperfusion injury therapeutics market in 2021. Drugs are widely accepted and established form of treatment for IRIs. These drugs, which target inflammation or oxidative stress, could effectively reduce the damage caused by IRIs and improve patient outcomes. Additionally, development of new and more effective drugs for treating IRI is ongoing. This is expected to drive the drug therapy segment in the next few years.
Based on injury type, the heart injury segment accounted for the largest share of the global market in 2021. Heart injury is a common type of IRI. Heart attack is a leading cause of death and disability across the world. Furthermore, advances in medical technology, such as development of new drugs and procedures for treating heart attacks, is projected to augment the heart injury segment.
North America dominated the global ischemia reperfusion injury therapeutics industry in 2021. Incidence of IRI is high in the region due to significant prevalence of cardiovascular diseases and large number of surgeries performed. Additionally, well-established healthcare infrastructure enables early diagnosis and treatment of IRI in North America. Governments in the region support the development and promotion of new treatments for IRI through funding and incentives for research & development. High healthcare expenditure also contributes to the growth of the market in North America, as patients have access to advanced treatments and technologies.
The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. This is ascribed to increase in geriatric population, which is more susceptible to IRI, and rise in awareness among healthcare professionals and general public. Expanding healthcare infrastructure and increase in availability of advanced medical technologies contribute to market growth in the region. Furthermore, rise in number of surgical procedures and increase in focus on organ transplantation drive the market in Asia Pacific.
This report provides profiles of leading players operating in the global ischemia reperfusion injury therapeutics market. These include Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., SBI Pharmaceuticals, Faraday Pharmaceuticals, and Zealand Pharma A/S. These players engage in merger & acquisition, strategic collaborations, and new product launches to expand market presence.
Leading players have been profiled in the report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 2.3 Bn |
|
Forecast (Value) in 2031 |
More than US$ 3.2 Bn |
|
Growth Rate (CAGR) 2022-2031 |
3.5% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 2.3 Bn in 2021
It is projected to reach more than US$ 3.2 Bn by 2031
The CAGR is anticipated to be 3.5% from 2022 to 2031
The drug therapy segment accounted for significant share in 2021
North America is expected to account for the largest share during the forecast period.
Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Faraday Pharmaceuticals, SBI Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., and Zealand Pharma A/S.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ischemia Reperfusion Injury Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Development
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. COVID 19 Impact on Industry
6. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Drug Therapy
6.3.2. Medicated Gases
6.3.3. Others
6.4. Market Attractiveness Analysis, by Treatment
7. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Injury Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Injury Type, 2017–2031
7.3.1. Heart Injury
7.3.2. Kidney Injury
7.3.3. Intestine Injury
7.3.4. Others
7.4. Market Attractiveness Analysis, by Injury Type
8. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2017–2031
10.2.1. Drug Therapy
10.2.2. Medicated Gases
10.2.3. Others
10.3. Market Value Forecast, by Injury Type, 2017–2031
10.3.1. Heart Injury
10.3.2. Kidney Injury
10.3.3. Intestine Injury
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Injury Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Drug Therapy
11.2.2. Medicated Gases
11.2.3. Others
11.3. Market Value Forecast, by Injury Type, 2017–2031
11.3.1. Heart Injury
11.3.2. Kidney Injury
11.3.3. Intestine Injury
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Injury Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Drug Therapy
12.2.2. Medicated Gases
12.2.3. Others
12.3. Market Value Forecast, by Injury Type, 2017–2031
12.3.1. Heart Injury
12.3.2. Kidney Injury
12.3.3. Intestine Injury
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Injury Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Drug Therapy
13.2.2. Medicated Gases
13.2.3. Others
13.3. Market Value Forecast, by Injury Type, 2017–2031
13.3.1. Heart Injury
13.3.2. Kidney Injury
13.3.3. Intestine Injury
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Injury Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Drug Therapy
14.2.2. Medicated Gases
14.2.3. Others
14.3. Market Value Forecast, by Injury Type, 2017–2031
14.3.1. Heart Injury
14.3.2. Kidney Injury
14.3.3. Intestine Injury
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment
14.6.2. By Injury Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Amyndas Pharmaceuticals LLC
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Angion
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Bolder Biotechnology
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Opsona Therapeutics Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Pharming Group NV
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Prolong Pharmaceuticals
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Prothix BV
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Stealth BioTherapeutics, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Zealand Pharma A/S
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. Faraday Pharmaceuticals
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.11. SBI Pharmaceuticals
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
List of Tables
Table 01: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031
Table 03: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 06: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031
Table 07: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 08: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 10: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031
Table 11: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 14: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031
Table 15: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 18: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031
Table 19: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 22: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031
Table 23: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 03: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 04: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031
Figure 05: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031
Figure 06: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 07: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 08: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Region, 2021 and 2031
Figure 09: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Region, 2022–2031
Figure 10: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 12: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 13: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031
Figure 14: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031
Figure 15: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 16: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 17: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country, 2021 and 2031
Figure 18: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
Figure 19: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 20: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 21: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 22: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031
Figure 23: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031
Figure 24: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 25: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 26: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 27: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 28: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 29: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 30: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 31: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031
Figure 32: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031
Figure 33: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 34: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 35: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 36: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 37: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 38: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 39: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 40: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031
Figure 41: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031
Figure 42: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 43: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 44: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 45: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 46: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 48: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 49: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031
Figure 50: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031
Figure 51: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031
Figure 52: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 53: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 54: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 55: Global Ischemia Reperfusion Injury Therapeutics Market Share Analysis, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ischemia Reperfusion Injury Therapeutics Market
